Cargando…
A novel proteasome inhibitor NPI-0052 as an anticancer therapy
Proteasome inhibitor Bortezomib/Velcade has emerged as an effective anticancer therapy for the treatment of relapsed and/or refractory multiple myeloma (MM), but prolonged treatment can be associated with toxicity and development of drug resistance. In this review, we discuss the recent discovery of...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360698/ https://www.ncbi.nlm.nih.gov/pubmed/17047643 http://dx.doi.org/10.1038/sj.bjc.6603406 |